What is it about?
Adjuvant mitotane following surgery for adrenocortical carcinoma reduces significantly the risk of tumor recurrence and prolongs recurrence-free survival.
Featured Image
Why is it important?
Adrenocortical carcinoma has a high propensity to recur even after complete surgical removal of the primary tumor. Prevention of recurrences is key in the management of affected patients.
Perspectives
We have confirmed after about 10 additional years of follow-up the outcome of a previous study of ours adding a further piece of evidence in favor of adjuvant mitotane therapy. The issue remains however matter of contention until results of prospective studies will be available.
Prof Massimo Terzolo
University of Turin
This is a confirmatory study, suggesting that adjuvant mitotane therapy has a favorable effect in patients operated for adrenal carcinoma.
Massimo Mannelli
Universita degli Studi di Firenze
Read the Original
This page is a summary of: Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma, The Journal of Clinical Endocrinology & Metabolism, January 2017, Endocrine Society,
DOI: 10.1210/jc.2016-2894.
You can read the full text:
Contributors
The following have contributed to this page
